

PRODUCT INFORMATION



TNFRSF7/CD27 Extracellular Domain (human, recombinant)


Item No. 31828

Overview and Properties

Synonyms: TNFRSF7, Tp55, Tumor Necrosis Factor Receptor Superfamily Receptor 7
Source: Active recombinant C-terminal human IgG1 Fc-His-tagged CD27 expressed in HEK293 cells
Amino Acids: 21-192
Uniprot No.: P26842
Molecular Weight: 47.2 kDa
Storage: -80°C (as supplied)
Stability: ≥1 year
Purity: ≥95% estimated by SDS-PAGE
Supplied in: Lyophilized from sterile PBS, pH 7.4
Endotoxin Testing: <1.0 EU/μg determined by the LAL endotoxin assay
Bioactivity: See figures for details


Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Images



Lane 1: MW Markers
Lane 2: CD27 Extracellular Domain

SDS-PAGE Analysis of CD27 Extracellular Domain. This protein has a calculated molecular weight of 47.2 kDa. It has an apparent molecular weight of approximately 65 kDa by SDS-PAGE under reducing conditions due to glycosylation.



Binding Ability of CD27 Extracellular Domain. Immobilized CD27 Extracellular Domain at 2 μg/ml (100 μl/well) can bind biotinylated human CD70 with a linear range of 0.39-12.5 ng/ml.

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/13/2020

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

CD27, also known as tumor necrosis factor receptor superfamily receptor 7 (TNFRSF7), is a type I transmembrane glycoprotein with roles in T cell-mediated immunity.^{1,2} It is comprised of an extracellular domain containing three cysteine-rich domains (CRDs), a transmembrane domain, and a short cytoplasmic domain that facilitates intracellular signaling.¹ CD27 is expressed on a broad range of lymphocytes, including natural killer (NK), B, and T cells, with T cell CD27 expression increasing upon T cell receptor stimulation.³ Binding of homotrimeric CD70 to CD27 on antigen-primed T cells induces NF- κ B and MAPK signaling through TNF receptor-associated factors (TRAFs) and, when the T cell is stimulated by other factors, induces PI3K signaling to induce the co-stimulation and expansion of naïve CD4⁺ and CD8⁺ T cells.^{4,5} Knockout of CD27 reduces thymic development of regulatory T cell (Treg) precursors and enhances apoptosis of mature Tregs in mice. Levels of CD27-expressing plasma cells are increased in the periphery and positively correlate with the disease activity index and serum levels of anti-dsDNA autoantibodies in patients with systemic lupus erythematosus (SLE).⁶ Cayman's TNFRSF7/CD27 Extracellular Domain (human, recombinant) protein can be used for binding assay applications. This protein is a disulfide-linked homodimer. The reduced monomer, comprised of CD27 (amino acids 21-192) fused to His-tagged human IgG1 Fc at its C-terminus, consists of 420 amino acids, has a calculated molecular weight of 47.2 kDa, and a predicted N-terminus of Thr21 after signal peptide cleavage. As a result of glycosylation, the monomer migrates at approximately 65 kDa by SDS-PAGE under reducing conditions.

References

1. Buchan, S.L., Rogel, A., and Al-Shamkhani, A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. *Blood* **131(1)**, 39-48 (2018).
2. Grant, E.J., Nüssing, S., Sant, S., *et al.* The role of CD27 in anti-viral T-cell immunity. *Curr. Opin. Virol.* **22**, 77-88 (2017).
3. Hendriks, J., Gravestien, L.A., Tesselaar, K., *et al.* CD27 is required for generation and long-term maintenance of T cell immunity. *Nat. Immunol.* **1(5)**, 433-440 (2000).
4. Wyzgol, A., Müller, N., Fick, A., *et al.* Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. *J. Immunol.* **183(3)**, 1851-1861 (2009).
5. Wajant, H. Therapeutic targeting of CD70 and CD27. *Expert Opin. Ther. Targets* **20(8)**, 959-973 (2016).
6. Han, B.K., Olsen, N.J., and Bottaro, A. The CD27-CD70 pathway and pathogenesis of autoimmune disease. *Semin. Arthritis Rheum.* **45(4)**, 496-501 (2016).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM